Kir Devika, Munagala Mrudula
Department of Cardiology, University of Miami Miller School of Medicine, Jackson Memorial Hospital, Miami, FL, United States.
Front Cardiovasc Med. 2022 Apr 20;9:839483. doi: 10.3389/fcvm.2022.839483. eCollection 2022.
Heart failure through the spectrum of reduced (HFrEF), mid-range (or mildly reduced or HFmEF), and preserved ejection fraction (HFpEF), continues to plague patients' quality of life through recurrent admissions and high mortality rates. Despite tremendous innovation in medical therapy, patients continue to experience refractory congestive symptoms due to adverse left ventricular remodeling, significant functional mitral regurgitation (FMR), and right-sided failure symptoms due to significant functional tricuspid regurgitation (FTR). As most of these patients are surgically challenging for open cardiac surgery, the past decade has seen the development and evolution of different percutaneous structural interventions targeted at improving FMR and FTR. There is renewed interest in the sphere of left ventricular restorative devices to effect reverse remodeling and thereby improve effective stroke volume and patient outcomes. For patients suffering from HFpEF, there is still a paucity of disease-modifying effective medical therapies, and these patients continue to have recurrent heart failure exacerbations due to impaired left ventricular relaxation and high filling pressures. Structural therapies involving the implantation of inter-atrial shunt devices to decrease left atrial pressure and the development of implantable devices in the pulmonary artery for real-time hemodynamic monitoring would help redefine treatment and outcomes for patients with HFpEF. Lastly, there is pre-clinical data supportive of soft robotic cardiac sleeves that serve to improve cardiac function, can assist contraction as well as relaxation of the heart, and have the potential to be customized for each patient. In this review, we focus on the role of structural interventions in heart failure as it stands in current clinical practice, evaluate the evidence amassed so far, and review promising structural therapies that may transform the future of heart failure management.
射血分数降低的心衰(HFrEF)、射血分数中度降低(或轻度降低或HFmEF)以及射血分数保留的心衰(HFpEF),仍通过反复住院和高死亡率困扰着患者的生活质量。尽管药物治疗有了巨大创新,但由于不良的左心室重塑、严重的功能性二尖瓣反流(FMR)以及严重的功能性三尖瓣反流(FTR)导致的右侧心力衰竭症状,患者仍会出现难治性充血症状。由于这些患者中的大多数进行心脏直视手术具有挑战性,在过去十年中,针对改善FMR和FTR出现了不同的经皮结构干预措施的发展和演变。人们对左心室修复装置领域重新产生兴趣,以实现逆向重塑,从而改善有效每搏输出量和患者预后。对于患有HFpEF的患者,仍然缺乏改变疾病的有效药物治疗,并且由于左心室舒张功能受损和高充盈压,这些患者仍会反复出现心力衰竭加重。涉及植入房间隔分流装置以降低左心房压力的结构治疗以及用于实时血流动力学监测的肺动脉植入式装置的开发,将有助于重新定义HFpEF患者的治疗和预后。最后,有临床前数据支持软机器人心脏袖套,其有助于改善心脏功能、辅助心脏收缩和舒张,并且有可能为每个患者定制。在这篇综述中,我们关注结构干预在当前临床实践中的心力衰竭中的作用,评估迄今为止积累的证据,并回顾可能改变心力衰竭管理未来的有前景的结构治疗方法。